Evaluation of Safety and Efficacy of Using Seraffix LTB - (Laser Tissue Bonding) System

Seraffix15 enrolled

Overview

The purpose of this study is to evaluate the safety and effectiveness of using Seraffix LTB system for soft tissue bonding.

Dermatologic wounds can be closed by a variety of methods. The choice of a particular closure technique should be based on the patient, wound, tissue characteristics, and anatomic location. The purpose of these closure methods is an approximation of wound lips until the regenerate tissue reach a phase, where it is closed and can sustain the daily tensile forces. Several methods are used for wounds closure such as sutures, staples, tapes, tissue adhesives and laser energy. There have been two fundamental approaches to laser assisted bonding of tissues: 1. Laser welding-heating the approximated edges of cuts in tissues by a laser beam; 2. Laser soldering- applying a biological solder onto the approximated edges and heating the solder (and the underlying tissue). Seraffix has developed the Seraffix LTB (Laser Tissue Bonding) System - a laser system for soft tissue bonding. This innovative system includes features that make laser soldering suitable for clinical use. The Seraffix system is composed of CO2 laser device, propriety grip device (Clamps) and soldering agent (Human Albumin).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Dehiscence, Surgical Wound

Interventions

Seraffix LTBDEVICE

laser soldering for soft tissue wounds

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male/Female age 18-60. * Subject is scheduled for laparoscopic cholecystectomy surgery. * Subject able to comprehend and give informed consent for participation in this study. * Signed informed consent form. Exclusion Criteria: * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to screening. * Acute infection requiring intravenous antibiotics at the time of screening. * Bleeding, coagulation and or clotting disorders. * Diabetes mellitus: IDDM or NIDDM. * HIV positive or any other immunosuppressive disorder. * Renal failure (Serum creatinine \>2.0 mg/dl). * Inflammatory and or allergic diseases or condition of the skin: Psoriasis, Eczema or dermatitis. * Any concomitant infection - viral or bacterial. * Drug abuse. * Use of steroids. * Infection / abscess / pain in treatment target area. * Pregnancy or lactating. * History of keloid scarring. * Use of aspirin or antioxidants * Subject is suffering extreme general weakness. * Subject objects to the study protocol. * Known cognitive or psychiatric disorder * Concurrent participation in any other clinical study. * Physician objection.

Locations (1)

Haemek Medical Center

Afula, Israel

Outcomes

Primary Outcomes

Primary study endpoint will be to establish the safety of using the Seraffix System for tissue bonding and wounds closure. Safety will be established by paucity of serious adverse events and adverse events.

Time frame: 3 months

Secondary Outcomes

1. Re-intervention: A subject is scored a success (1) if he had No Re-intervention by 3 months; otherwise he is scored a failure (0). 2. Wound dehiscence of at least 50% of wound length:

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.